News Archive

ROCKVILLE, Md.–(BUSINESS WIRE)–Feb. 23, 2021– GlycoMimetics, Inc. (Nasdaq: GLYC) today announced the promotion of Eric Feldman, M.D., to Senior Vice President and Chief Medical Officer. Dr. Feldman joined the Company in 2019 and was previously Vice President, Global Clinical Development.

“Eric is internationally recognized for his work in the development of new therapies for the treatment of leukemias and related bone marrow disorders, and in the past two years, has established himself as a leader in our management group as well as in the trenches with our clinical operations team. Having spent his career dedicated to patients with hematologic malignancies, he is especially well positioned to lead our uproleselan program as it advances through Phase 3 clinical trials. In addition, his extensive clinical research background will serve us well as we drive forward other programs in our pipeline,” said Rachel King, Chief Executive Officer.

This free webinar will feature a fireside chat-style conversation with Dr. Robert Scharpf (Delfi Diagnostics) and Dr. Christie Bergerson (Exponent). Drs. Scharpf and Bergerson will discuss how machine learning and artificial intelligence are impacting biomedical engineering and the wider world of human health.

Rich Bendis (BioHealth Innovation/BioTalk podcast) will facilitate the discussion. View the speaker bios for more information.

After the main session, participants will have the opportunity to join one of three, smaller breakout sessions:

• Meet and Greet with the Featured Speakers – Continue the conversation with Drs. Scharpf and Bergerson for an informal Q&A session about their work and the field.
• Careers at the Intersection of Artificial Intelligence and Biotechnology – Join Rich Bendis and other industry representatives in exploring career opportunities in the emerging biotechnology, data science, and public health fields. 
• What is Biocomputational Engineering? Learn about UMD’s new bachelor’s degree – Join program staff to learn about the exciting new University of Maryland degree aimed at preparing students for careers in the data science and biotechnology sector. Launching in Fall 2021 at the Universities at Shady Grove, this program is conveniently located in Rockville, MD – a biotech powerhouse just outside the nation’s capital.

COLUMBIA, Md. (February 24, 2021)—TEDCO, Maryland’s economic engine for technology companies, announced today the appointment of Jack Miner as the chief investment officer. He begins his tenure with TEDCO on March 1, 2021.

“Jack brings many years of venture capital and leadership experience to fill this critical role at TEDCO,” said Troy LeMaile-Stovall, TEDCO’s CEO and executive director. “Leveraging his extensive knowledge of the entrepreneurial and venture capital community, we’re looking forward to the impact he will make in fostering TEDCO’s mission to better serve our entrepreneurs.” 

Many policy decisions on the pandemic — in Washington and locally — are driven by an online data tool developed at Johns Hopkins University. Correspondent David Begnaud spoke to one of the people behind the site.

Image: https://www.kctv5.com – From Video

PLYMOUTH MEETING, Pa. and GERMANTOWN, Md. and HILDEN, Germany, Feb. 24, 2021 /PRNewswire/ — QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and INOVIO Pharmaceuticals (NASDAQ: INO) today announced an extension of their partnership with a new master collaboration agreement to develop liquid biopsy-based companion* diagnostic products based on next-generation sequencing (NGS) technology to complement INOVIO’s therapies. (*Complementary when referring to the US regulatory pathway.)

Richmond-based pharmaceutical development company Phlow Corp. has formed a partnership with a nonprofit organization that will involve opening new laboratory operations in downtown Richmond.

Phlow, which is working to build the supply of medicines that face shortages in the U.S. market, said Monday that it has formed a strategic alliance with United States Pharmacopeia to develop a new laboratory operation in the Virginia Bio+Tech Research Park.

Image: Daniel Sangjib Min – Times-Dispatch

The Defense Advanced Research Projects Agency will now allow small businesses that are majority owned by private equity firms to bid on both Small Business Innovation Research and Small Business Technology Transfer opportunities.

Congratulations to the BHI Board-members who made the list.

• Pete Briskman – Executive Managing Director Maryland , JLL
• Ron Daniels – President, Johns Hopkins University
• Dr. Jay Perman – Chancellor of the University System of Maryland

Biographer Robert Caro, in discussing his craft, wrote that “power reveals.” It reveals the true character of people, the nature of their endeavors, their goals and ambitions.

Welcome to The Daily Record’s inaugural Power 100 List.

We are recognizing the men and women across Maryland who are shaping our businesses, governments, nonprofits, law firms and other critical institutions. In essence, they are playing an outsize role in the culture, lifestyle, civic conversation and economic fortunes of Maryland.

The LaunchPort™ announced today that Novel Microdevices (http://www.noveldx.com) has moved to their Medtech venture center in Port Covington, Baltimore, and has established The LaunchPort™ as its primary location for their GMP development efforts.

The National Institutes of Health (NIH) small business programs, which include the Small Business Innovation Research (SBIR) and the Small Business Technology Transfer (STTR) programs, are the largest source of early stage capital for life sciences startups in the United States.  The grant money helps startups accelerate their discoveries and put their discoveries into clinical trials.  The grants awarded are just that, a grant and not a loan; there is no requirement to pay back the money. The NIH grants $1.2 billion dollars every year in the combined SBIR and STTR programs.